Kambara Kenta - First Department of Internal Medicine, Toyama University Hospital

基本信息

浏览量：22

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 53 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report

Takahiro Hirai,Minehiko Inomata, Shuhei Minatoyama, Moe Hashizume,Naoki Takata,Kana Hayashi,Zenta Seto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shinichi Tanaka,Akira Noguchi,Tsutomu Sato

In vivo/In Vivono. 3 (2024): 1509-1511

引用0浏览0WOS引用

An Observational Study on the Efficacy of Targeted Therapy for Pulmonary Sarcomatoid Carcinoma

Discover Oncologyno. 1 (2024): 1-9

引用0浏览0WOS引用

Immune Checkpoint Inhibitor Therapy for Patients with Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy

Minehiko Inomata, Shuhei Minatoyama,Naoki Takata,Kana Hayashi,Takahiro Hirai,Zenta Seto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa, Kei Matsuyama,Ryuji Hayashi, Shoko Matusi,Kazuyuki Tobe

ANTICANCER RESEARCHno. 3 (2024): 1241-1245

引用0浏览0WOS引用

Comparison of the Efficacy of First‑/second‑generation EGFR‑tyrosine Kinase Inhibitors and Osimertinib for EGFR‑mutant Lung Cancer with Negative or Low PD‑L1 Expression

Molecular and clinical oncologyno. 6 (2024)

引用0浏览0WOS引用

Associations of Immune Checkpoint Inhibitor Therapy Efficacy with Clinical Parameters and Tumor‑infiltrating CD68‑positive Cell Counts in Patients with EGFR‑mutant Non‑small Cell Lung Cancer

Takeshi Tsuda,Kensuke Suzuki,Minehiko Inomata,Kana Hayashi,Isami Mizushima,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Yasuaki Masaki,Hirokazu Taniguchi,Kazuyuki Tobe

MOLECULAR AND CLINICAL ONCOLOGYno. 5 (2023)

引用1浏览0WOS引用

Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors

Minehiko Inomata,Masahiro Matsumoto,Kana Hayashi,Zenta Seto,Takahiro Hirai,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe

Anticancer researchno. 7 (2023): 3241-3246

引用0浏览0WOS引用

Peripheral CD4 Memory T Cells Predict the Efficacy of Immune Checkpoint Inhibitor Therapy in Patients with Non-Small Cell Lung Cancer

Minehiko Inomata,Masahiro Matsumoto,Naoki Takata,Kana Hayashi,Zenta Seto,Takahiro Hirai,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe

Scientific reportsno. 1 (2023)

引用0浏览0WOSNATURE引用

Association of Tumor PD-L1 Expression with Time on Treatment Using EGFR-TKIs in Patients with EGFR-Mutant Non-small Cell Lung Cancer

Minehiko Inomata,Masahiro Matsumoto,Isami Mizushima,Zenta Seto,Kana Hayashi,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe

Cancer Diagnosis & Prognosisno. 3 (2022): 324-329

引用6浏览0WOS引用

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Minehiko Inomata,Masahiro Matsumoto,Isami Mizushima,Kana Hayashi,Zenta Seto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe

The Egyptian Journal of Bronchology（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn